CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 616 target
Drug / intervention
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)procedure
Likely dose
Not stated in record
Key inclusion· 10
  • ✓Newly treated patients without prior chemotherapy, radiotherapy or antitumor therapy
  • ✓Age 18-80 years
  • ✓Male or non-pregnant/non-lactating female
  • ✓Pathologically confirmed gastric adenocarcinoma planned for laparoscopic radical gastrectomy
Key exclusion· 13
  • ✕Lymph node Bulky N2 status: at least one lymph node ≥3cm or three consecutive lymph nodes each ≥1.5cm
  • ✕Pregnant or lactating women
  • ✕Other malignant tumors within 5 years
  • ✕Preoperative temperature ≥38°C or infectious diseases requiring systematic treatment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05871099
NCT05871099Phase 3RecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Laparoscopic Gastrectomy With D2 Lymphadenectomy: A Phase III Multicenter Prospective Randomized Controlled Clinical Trial

The Affiliated Hospital of Qingdao University·interventional·Posted May 23, 2023·Updated Mar 6, 2026

In Brief

A Phase 3 clinical trial evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer. Currently recruiting, targeting 616 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\~8 cycles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer
CountriesChina
CollaboratorsShandong Cancer Hospital and Institute, Chinese PLA General Hospital, Zibo Central Hospital, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Jinan Central Hospital, Qilu Hospital of Shandong University, Yantai Yuhuangding Hospital, Nanfang Hospital, Southern Medical University, Shandong First Medical University, The First Affiliated Hospital of Nanchang University, Hebei Medical University Fourth Hospital, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Tianjin Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhongnan Hospital, Brigham and Women's Hospital, Second Xiangya Hospital of Central South University, Weihai Municipal Hospital, Mountain University Cancer Hospital, Ruijin Hospital

Timeline

Phase 3Recruiting
202320242025202620272028202920302031
First PostedMay 23, 2023
Enrollment StartNov 20, 2022
Primary CompletionDec 1, 2030
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 3.1 years agoPrimary completion in 4.4 years

Interventions

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)procedure

Experimental group receive HIPEC two times after laproscopic gastrectomy